Barrett's oesophagus and adenocarcinoma

World Journal of Surgical Oncology

Volumn 2, Issue , 2004, Pages

  Caygill, Christine P J ^a   Watson, Antony ^a   Lao Sirieix, Pierre ^b   Fitzgerald, Rebecca C ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b HUTCHISON MRC RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; OMEPRAZOLE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PRODRUG; PROKINETIC AGENT; PROTEIN FOS; PROTON PUMP INHIBITOR; PROTOPORPHYRIN; RAS PROTEIN; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; TRANSFORMING GROWTH FACTOR ALPHA;

ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER GROWTH; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; DEMOGRAPHY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; ESOPHAGUS CARCINOMA; ESOPHAGUS STRICTURE; HEALTH SURVEY; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; LASER SURGERY; LIFESTYLE; MOLECULAR BIOLOGY; ONCOGENE; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING; UNITED KINGDOM;

EID: 33646221727     PISSN: 14777819     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7819-2-12     Document Type: Review

References (231)

1. Barrett NR: Chronic peptic ulcer of the oesophagus and "oesophagitis". Br J Surg 1950, 38:175-182.
2. Allison PR, Johnstone AS: The oesophagus lined with gastric mucous membrane. Thorax 1953, 8:87-101.
3. Moersch R, Ellis FH, McDonald JR: Pathologic changes occurring in severe reflux oesophagitis. Surg Gynecol Obstet 1959, 108:476-484.
4. Hayward J: The lower end of the oesophagus. Thorax 1961, 16:36-41.
5. Bremner CG, Lynch VP, Ellis FH: Barrett's oesophagus: congenital or acquired? An experimental study of oesophageal mucosal regeneration in the dog. Surgery 1970, 68:209-216.
6. Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK: The histological spectrum of Barrett's oesophagus. N Engl J Med 1976, 295:476-480.
7. Naef AP, Savary M, Ozzello L: Columnar-lined lower oesophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's oesophagus with 12 adenocarcinomas. J Thorac Cardiovasc Surg 1975, 70:826-835.
8. Haggitt RC, Tryzelaar J, Ellis FH, Colcher H: Adenocarcinoma complicating columnar epithelium-lined (Barrett's) oesophagus. Am J Clin Pathol 1978, 70:1-5.
9. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR: Barrett's oesophagus: comparison of benign and malignant cases. Ann Surg 1983, 198:554-565.
10. Reid BJ, Haggitt RC, Rubin LE, Rabinovitch PS: Barrett's oesophagus: correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987, 93:1-11.
11. Spechler SJ, Goyal RK: The columnar-lined oesophagus, intestinal metaplasia and Norman Barrett. Gastroenterology 1996, 110:614-621.
12. Schnell TG, Sontag SJ, Chejfec G: Adenocarcinoma arising in tongues or short segments of Barrett's oesophagus. Dig Dis Sci 1992, 37:137-143.
13. Cameron AJ, Lomboy CT, Pera M, Carpenter HA: Adenocarcinoma of the oesophagogastric junction and Barrett's oesophagus. Gastroenterology 1995, 109:1541-1546.
14. Clark GW, Smyrk TC, Burdiles P, Hoeft SF, Peters JH, Kiyabu M, Hinder RA, Bremner CG, DeMeester TR: Is Barrett's metaplasia the source of adenocarcinomas of the cardia? Arch Surg 1994, 129:609-614.
15. Clark GWB, Ireland AP, Peters JH, Chandrasoma P, DeMeester TR, Bremner CG: Short-segment Barrett's oesophagus: a prevalent complication of gastroesophageal reflux disease with malignant potential. J Gastrointest Surg 1997, 1:113-122.
16. Spechler SJ, Zeroogian JM, Antonioli DA, Wang HH, Goyal RK: Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994, 344:1533-1536.
17. Trudgill NJ, Suvarna SK, Kapur KC, Riley SA: Intestinal metaplasia at the squamocolumnar junction in patients attending for diagnostic gastroscopy. Gut 1997, 41:585-589.
18. Nandurkar S, Talley NJ, Martin CJ, Ng TH, Adams S: Short segment Barrett's oesophagus: prevalence, diagnosis and associations. Gut 1997, 40:710-715.
19. Weston AP, Krmpotich P, Makdisi WF, Cherian R, Dixon A, McGregor DH, Banerjee SK: Short segments Barrett's oesophagus; clinical and histological features associated endoscopic findings, and association with gastric intestinal metaplasia. Am J Gastroenterol 1996, 91:981-986.
20. Winters Jr C, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker 3rd JF, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS, Cattau Jr EL: Barrett's oesophagus - a prevalent occult complication of gastro-oesophageal reflux. Gastroenterology 1987, 92:118-124.
21. Stein HJ, Hoeft S, DeMeester TR: Reflux and motility pattern in Barrett's oesophagus. Dis Oesophagus 1992, 5:21-28.
22. Attwood SEA, Ball CS, Barlow AP, Jenkinson L, Norris TL, Watson A: Role of intragastric and intraoesophageal alkalinisation in the genesis of complications in Barrett's columnar lined lower oesophagus. Gut 1993, 34:11-15.
23. Kauer WK, Peters JH, DeMeester TR, Ireland AP, Bremner CG, Hagen JA: Mixed reflux of gastric and duodenal juices more harmful to the oesophagus than gastric juice alone. The need for surgical therapy re-emphasised. Ann Surg 1995, 222:523-533. discussion 531-33
24. Ball CS, Watson A: Acid sensitivity in reflux oesophagitis with and without complications. Gut 1988, 29:729.
25. Cameron A, Zinmeister A, Ballard D, Carney J: Prevalence of columnar-lined (Barrett's) oesophagus. Comparison of population-based clinical and autopsy findings. Gastroenterology 1990, 99:1918-1922.
26. Conio M, Cameron AJ, Romero Y, Branch CD, Schleck CD, Burgart LJ, Zinsmeister AR, Melton 3rd LJ, Locke 3rd GR: Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted Country, Minnesota. Gut 2001, 48:304-309.
27. Bartlesman JFWM, Hameeteman W, Tytgat GNJ: Barrett's oesophagus. Eur J Cancer Prev 1992, 1:323-325.
28. Solaymani-Dodaran M, Coupland C, Logan RFA: Risk of oesophageal cancer in Barrett's oesophagus and in gastro-oesophageal reflux. Gut 2003, 52:A20.
29. Cameron AJ, Lomboy CT: Barrett's oesophagus: age prevalence and extent of columnar epithelium. Gastroenterology 1992, 103:1241-1245.
30. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali MH, Levi S: A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. Eur J Gastroenterol Heptol 1999, 11:1355-1358.
31. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslet MC, Pounder RE: Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. Gastroenterology 1999, 116(suppl 2):A351.
32. Todd JA, Johnston DA, Dillon JF: Incidence of Barrett's oesophagus and oesophagitis at upper GI endoscopy. Gut 2000, 46(suppl II):A94.
33. Watson A, Caygill CPJ: The frequency of development of adenocarcinoma in Barrett's oesophagus - implications for surveillance. Gastroenterology 2002, 122:A350.
34. Atkinson M, Iftikhar SY, James PD, Robertson CS, Steele RJC: The early diagnosis of oesophageal adenocarcinoma by endoscopic screening. Eur J Cancer Prev 1992, 1:327-330.
35. Reed PI: The changing pattern of adenocarcinoma of the oesophagogastric junction. In The oesophagogastric Junction Edited by: Giuli R, Galmiche J-P, Jamieson GG, Scarpignato C. Montrouge, John Libby 1988, 1131-1140.
36. Veith M, Masoud B, Meining A, Stolte M: Helicobacter pylori infection: protection against Barrett's mucosa and neoplasia? Digestion 2000, 62:225-231.
37. Sharma P: Helicobactor pylori: a debated factor in gastroesophageal reflux disease. Dig Dis 2001, 19:127-133.
38. Koop H: Gastroesophageal reflux disease and Barrett's oesophagus. Endoscopy 2002, 34:97-103.
39. Iftikhar SY, James PD, Steele RJC, Hardcastle JD, Atkinson M: Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992, 33:1155-1158.
40. Van der Burgh A, Dees J, Hop WCJ, van Blankenstein M: Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996, 39:5-8.
41. Cox MA, Nwokolo CU, Loft DE: Screening for Barrett's oesophagus is worthwhile. Gut 1997, 41(suppl III):E20.
42. Caygill CPJ, Reed PI, McIntyre A, Hill MJ: The UK National Barrett's Oesophagus Registry: a study between two centres. Eur J Cancer Prev 1998, 7:161-164.
43. Caygill C, Reed P, Watson A, Hill M: UK National Barrett's Oesophagus Registry: An Update. Gut 2000, 47(suppl III):A68.
44. Macdonald CE, Wicks AC, Playford RJ: Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study. BMJ 2000, 321:1252-1255.
45. Csendes A, Smok G, Quiroz J, Burdiles P, Rojas J, Castro C, Henriquez A: Clinical, endoscopic, and functional studies in 408 patients with Barrett's oesophagus, compared to 174 cases of intestinal metaplasia of the cardia. Am J Gastroenterol 2002, 97:554-560.
46. Cotton JP, Lopez M, McLeod S, Todd JA, Johnston DA, Setmarr PW, Dillon DF: Gender differences in the epidemiology of GORD. Gut 2003, 52(suppl I):A46 [Abstract 168].
47. van Blankenstein M, Caygill CPJ, Johnston BJ: The prevalence of Barrett's oesophagus (BO) in a U.K. centre over 15 years. Gut 2002, 50(suppl II):A123.
48. Caygill CPJ, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ: Lifestyle Factors and Barrett's Oesophagus. Am J Gastroenterol 2002, 97:1328-1331.
49. Gray MR, Donnelly RJ, Kingsnorth JN: The role of smoking and alcohol in metaplasia and cancer risk in Barrett's columnar lined epithelium. Gut 1993, 34:727-731.
50. Logan RFA, Riddick A: Barrett's oesophagus - are smoking and drinking alcohol risk factors? Gut 1990, 31:A603.
51. Reed PI, Watson A: UK National Barrett's oesophagus Registry. Eur J Cancer Prev 1996, 5:207.
52. Caygill CPJ, Reed PI, Hill MJ, Watson A: An initial comparison of nine centres registering patients with the UK national Barrett's oesophagus Registry (UKBOR). Eur J Cancer Prev 1999, 8:539-542.
53. Caygill CPJ, Reed PI, Hill MJ, Watson A: The UK National Barrett's Oesophagus Registry: a progress report. Eur J Cancer Prev 1999, 8:354.
54. The health of the nation: One year on Her Majesty'sStationary Office 1993, 50.
55. Gatenby PAC, Caygill CPJ, Charlett A, Fitzgerald R, Watson A: Length of Barrett's oesophagus segment: Demographic associations and cancer risk. Gut 2003, 52(suppl I):A41.
56. Blot WJ, Devesa SS, Kneller RW, Fraumeni Jr JF: Rising incidence of adenocarcinoma of the oesophagus and gastric cardia. JAMA 1991, 265:1287-1289.
57. Watson A: Barrett's oesophagus - 50 years on. Br J Surg 2000, 87:529-531.
58. Cheng KK, Sharp L, McKinney PA, Logan RF, Chilvers CE, Cook-Mozaffari P, Ahmed A, Day NE: A case-control study of oesophageal adenocarcinoma in women; a preventable disease. Br J Cancer 2000, 83:127-132.
59. Lagergren J, Bergstrom R, Lindgren A, Nyren O: The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000, 85:340-346.
60. Romero Y, Cameron AJ, Locke 3rd GR, Schaid DJ, Slezak JM, Branch CD, Melton 3rd LJ: Familial aggregation of gastroesophageal reflux in patients with Barrett's oesophagus and oesophageal adenocarcinoma. Gastroenterology 1997, 113:1449-1456.
61. Lagergren J, Bergstrom R, Lindgren A, Nyren O: Symptomatic gastroesophageal reflux as a risk factor for oesophageal adenocarcinoma. N Engl J Med 1999, 340:825-832.
62. Weston AP, Badr AS, Hassanein RS: Prospective multivariate analysis of factors predictive of complete regression of Barrett's oesophagus. Am J Gastroenterol 1999, 94:3420-3426.
63. Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ: Hiatal hernia size, Barrett's length and severity of acid reflux are all risk factors for oesophageal adenocarcinoma. Am J Gastroenterol 2002, 97:1930-1936.
64. Fein Fein M, Ireland AP, Ritter MP, Peters JH, Hagen JA, Bremner CG, DeMeester TR: Duodenogastric reflux potentiates the injurious effects of gastroesophageal reflux. J Gastrointest Surg 1997, 1:27-33.
65. Eisen GM, Sandler RS, Murray S, Gottfried M: The relationship between gastroesophageal reflux disease and its complications with Barrett's oesophagus. Am J Gastroenterol 1997, 92:27-31.
66. Fletcher J, Wirtz A, Young J, Vallance R, McColl KEL: Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001, 121:775-783.
67. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW: Risk factors for the development of adenocarcinoma in columnar-lined (Barrett's) oesophagus. The Rotterdam Oesophageal Tumour Study Group. Cancer 1993, 72:1155-58.
68. Gammon MD, Schoenberg JB, Ahsan H, Risch HA, Vaughan TL, Chow WH, Rotterdam H, West AB, Dubrow R, Stanford JL, Mayne ST, Farrow DC, Niwa S, Blot WJ, Fraumeni Jr JF: Tobacco, alcohol and socio-economic status and adenocarcinoma of the oesophagus and gastric cardia. J Nat Cancer Institute 1997, 89:1277-1284.
69. Vaughan TL, Farrow DC, Hansten PD, Chow WH, Gammon MD, Risch HA, Stanford JL, Schoenberg JB, Mayne ST, Rotterdam H, Dubrow R, Ahsan H, West AB, Blot WJ, Fraumeni Jr JF: Risk of oesophageal and gastric adenocarcinomas in relation to use of calcium channel blockers, asthma drugs and other medications that promote gastroesophageal reflux. Cancer Epidemiol Biomarkers Prev 1998, 7:749-756.
70. Chow WH, Blot WJ, Vaughan TL, Risch HA, Gammon MD, Stanford JL, Dubrow R, Schoenberg JB, Mayne ST, Farrow DC, Ahsan H, West AB, Rotterdam H, Niwa S, Fraumeni JF Jr: Body mass index and risk of adenocarcinoma of the oesophagus and gastric cardia. J Nat Cancer Institute 1998, 90:150-155.
71. Farrow DC, Vaughan TL, Sweeney C, Gammon MD, Chow WH, Risch HA, Stanford JL, Hansten PD, Mayne ST, Schoenberg JB, Rotterdam H, Ahsan H, West AB, Dubrow R, Fraumeni JF Jr, Blot WJ: Gastroesophageal reflux disease - use of H2 receptor antagonists and risk of oesophageal and gastric cancer. Cancer Causes Control 2000, 11:231-238.
72. Weston AP, Sharma P, Topalovski M, Richards R, Cherian R, Dixon A: Long term follow up of Barrett's high-grade dysplasia. Am J Gastroenterol 2000, 95:1888-1893.
73. Schnell TG, Sontag SJ, Chejfec G, Aranha G, Metz A, O'Connell S, Seidel UJ, Sonnenberg A: Long-term non-surgical management of Barrett's oesophagus with high-grade dysplasia. Gastroenterology 2001, 120:1607-1619.
74. Buttar NS, Wang KK, Sebo TJ, Riehle DM, Krishnadath KK, Lutzke LS, Anderson MA, Petterson TM, Burgart LJ: Extent of high-grade dysplasia in Barrett's oesophagus correlates with risk of adenocarcinoma. Gastroenterology 2001, 120:1630-1639.
75. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR: The diagnosis of low-grade dysplasia in Barrett's oesophagus and its implications for disease progression. Am J Gastroenterol 2000, 95:3383-3387.
76. Montgomery E, Bronner MP, Greenson JK, Haber MM, Hart J, Lamps LW, Lauwers GY, Lazenby AJ, Lewin DN, Robert ME, Washington K, Goldblum JR: Are ulcers a marker for invasive carcinoma in Barrett's oesophagus? Data from a diagnostic variability study with clinical follow up. Am J Gastroenterol 2002, 97:27-31.
77. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100:57-70.
78. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG: Barrett's oesophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989, 96:1249-1256.
79. Drewitz DJ, Sampliner RE, Garewal HS: The incidence of adenocarcinoma in Barrett's oesophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997, 92:212-215.
80. Locke G, Talley N, Fett S, Zinsmeister A, Melton L: Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-1456.
81. Haggitt RC, Dean PJ: Adenocarcinoma in Barrett's epithelium. In: Barrett's oesophagus: pathophysiology, diagnosis and management Edited by: Goyal RK. New York, Elsevier 1985, 153-166.
82. Jass J, Filipe M: The mucin profiles of normal gastric mucosa, intestinal metaplasia and its variants and gatsric carcinoma. Histochem J 1981, 13:931-939.
83. Filipe M: Mucins in the gastrointestinal epithelium: A review. Invest Cell Pathol 1979, 2:195-216.
84. Hong MK, Laskin WB, Herman BE, Johnston MH, Vargo JJ, Steinberg SM, Allegra CJ, Johnston PG: Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's oesophagus. Cancer 1995, 75:423-429.
85. Herbst JJ, Berenson MM, McCloskey DW, Wiser WC: Cell proliferation in oesophageal columnar epithelium (Barrett's oesophagus). Gastroenterology 1978, 75:683-687.
86. Gray MR, Hall PA, Nash J, Ansari B, Lane DP, Kingsnorth AN: Epithelial proliferation in Barrett's oesophagus by proliferating cell nuclear antigen immunolocalisation. Gastroenterology 1992, 103:1769-1776.
87. Iftikhar SY, Steele RJ, Watson S, James PD, Dilks K, Hardcastle JD: Assessment of proliferation of squamous, Barrett's and gastric mucosa in patients with columnar lined Barrett's oesophagus. Gut 1992, 33:733-737.
88. Gillen P, McDermott M, Grehan D, Hourihane DO, Hennessy TP: Proliferating cell nuclear antigen in the assessment of Barrett's mucosa. Br J Surg 1994, 81:1766-1768.
89. Filipe MI, Jankowski J: Growth factors and oncogenes in Barrett's oesophagus and gastric metaplasia. Endoscopy 1993, 25:637-641.
90. Brito MJ, Filipe MI, Linehan J, Jankowski J: Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int J Cancer 1995, 60:27-32.
91. Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D, Singer J, Peters JH, Danenberg KD, Demeester TR, Danenberg PV: Vascular endothelial growth factor and basic fibroblast growth factor expression in oesophageal adenocarcinoma and Barrett oesophagus. J Thorac Cardiovasc Surg 2003, 125:246-253.
92. Mukaida H, Toi M, Hirai T, Yamashita Y, Toge T: Clinical significance of the expression of epidermal growth factor and its receptor in oesophageal cancer. Cancer 1991, 68:142-148.
93. Iihara K, Shiozaki H, Tahara H, Kobayashi K, Inoue M, Tamura S, Miyata M, Oka H, Doki Y, Mori T: Prognostic significance of transforming growth factor-alpha in human oesophageal carcinoma. Implication for the autocrine proliferation. Cancer 1993, 71:2902-2909.
94. Jankowski J, McMenemin R, Hopwood D, Penston J, Wormsley KG: Abnormal expression of growth regulatory factors in Barrett's oesophagus. Clin Sci (Lond) 1991, 81:663-668.
95. Jankowski J, Coghill G, Hopwood D, Wormsley KG: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 1992, 33:1033-1038.
96. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991, 47:87-98.
97. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986, 319:230-234.
98. Flejou JF, Paraf F, Muzeau F, Fekete F, Henin D, Jothy S, Potet F: Expression of c-erbB-2 oncogene product in Barrett's adenocarcinoma: pathological and prognostic correlations. J Clin Pathol 1994, 47:23-26.
99. Hardwick RH, Shepherd NA, Moorghen M, Newcomb PV, Alderson D: c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol 1995, 48:129-132.
100. Walch A, Bink K, Gais P, Stangl S, Hutzler P, Aubele M, Mueller J, Hofler H, Werner M: Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal Cell Pathol 2000, 20:25-32.
101. Walch A, Specht K, Bink K, Zitzelsberger H, Braselmann H, Bauer M, Aubele M, Stein H, Siewert JR, Hofler H, Werner M: Her-2/neu gene amplification, elevated mRNA expression, and protein overexpression in the metaplasia-dysplasia-adenocarcinoma sequence of Barrett's oesophagus. Lab Invest 2001, 81:791-801.
102. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M: Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002, 118:60-66.
103. Nakamura T, Nekarda H, Hoelscher AH, Bollschweiler E, Harbeck N, Becker K, Siewert JR, Harbeck N: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's oesophagus. Cancer 1994, 73:1785-1794. Erratum in: Cancer 1994, 74:2396
104. Onwuegbusi BA, Fitzgerald RC: Impairment of TGFb signalling in Barrett's associated oesophageal adenocarcinoma: role of SMAD4. Gut 2003, 52:A44.
105. Lebman DA, Edmiston JS, Chung TD, Snyder SR: Heterogeneity in the transforming growth factor beta response of oesophageal cancer cells. Int J Oncol 2002, 20:1241-1246.
106. Garrigue-Antar L, Souza RF, Vellucci VF, Meltzer SJ, Reiss M: Loss of transforming growth factor-beta type II receptor gene expression in primary human oesophageal cancer. Lab Invest 1996, 75:263-272.
107. Souza RF, Garrigue-Antar L, Lei J, Yin J, Appel R, Vellucci VF, Zou TT, Zhou X, Wang S, Rhyu MG, Cymes K, Chan O, Park WS, Krasna MJ, Greenwald BD, Cottrell J, Abraham JM, Simms L, Leggett B, Young J, Harpaz N, Reiss M, Meltzer SJ: Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and oesophageal carcinomas, but not in gastric neoplasms. Hum Cell 1996, 9:229-236.
108. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987, 327:298-303.
109. Meltzer SJ, Zhou D, Weinstein WM: Tissue-specific expression of c-Ha-ras in premalignant gastrointestinal mucosae. Exp Mol Pathol 1989, 51:264-274.
110. Trautmann B, Wittekind C, Strobel D, Meixner H, Keymling J, Gossner L, Ell C, Hahn EG: K-ras point mutations are rare events in premalignant forms of Barrett's oesophagus. Eur J Gastroenterol Hepatol 1996, 8:799-804.
111. Lord RV, O'Grady R, Sheehan C, Field AF, Ward RL: K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J Gastroenterol Hepatol 2000, 15:730-736.
112. Galiana C, Lozano JC, Bancel B, Nakazawa H, Yamasaki H: High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human oesophagus. Mol Carcinog 1995, 14:286-293.
113. Cooper G: Oncogenes. Boston, Jones & Bartlett 1990, 225-244.
114. Sarbia M, Arjumand J, Wolter M, Reifenberger G, Heep H, Gabbert HE: Frequent c-myc amplification in high-grade dysplasia and adenocarcinoma in Barrett oesophagus. Am J Clin Pathol 2001, 115:835-840.
115. Persons DL, Croughan WS, Borelli KA, Cherian R: Interphase cytogenetics of oesophageal adenocarcinoma and precursor lesions. Cancer Genet Cytogenet 1998, 106:11-17.
116. Tselepis C, Morris CD, Wakelin D, Hardy R, Perry I, Luong QT, Harper E, Harrison R, Attwood SE, Jankowski JA: Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro. Gut 2003, 52:174-180.
117. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ: Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's oesophagus and associated adenocarcinomas. Cancer Res 1998, 58:2929-2934.
118. Morris CD, Armstrong GR, Bigley G, Green H, Attwood SE: Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 2001, 96:990-996.
119. van der Woude CJ, Jansen PL, Tiebosch AT, Beuving A, Homan M, Kleibeuker JH, Moshage H: Expression of apoptosis-related proteins in Barrett's metaplasia-dysplasia-carcinoma sequence: a switch to a more resistant phenotype. Hum Pathol 2002, 33:686-692.
120. Cheong E, Igali L, Harvey I, Mole M, Lund E, Johnson IT, Rhodes M: Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study. Aliment Pharmacol Ther 2003, 17:379-386.
121. Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN: Cyclooxygenase-2 expression in Barrett's oesophagus. Dig Dis Sci 2001, 46:785-789.
122. Abdalla SI, Sanderson IR, Fitzgerald RC: Cyclooxygenase-2 expression in columnar versus squamous phenotypes: Relationship to oesophageal inflammation and Barrett's oesophagus. Gastroenterology 2002, 122:A290.
123. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifico RJ, Krishnadath KK, Lutzke LS: The effect of selective cyclooxygenase-2 inhibition in Barrett's oesophagus epithelium: an in vitro study. J Natl Cancer Inst 2002, 94:422-429.
124. Souza RF, Shewmake K, Terada LS, Spechler SJ: Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's oesophagus. Gastroenterology 2002, 122:299-307.
125. Fitzgerald RC, Omary MB, Triadafilopoulos G: Altered sodium-hydrogen exchange activity is a mechanism for acid-induced hyperproliferation in Barrett's oesophagus. Am J Physiol 1998, 275:G47-55.
126. Morgan C, Alazawi W, Sirieix P, Freeman N, Coleman N, Fitzgerald RC: Immediate and early gene response to in vitro acid exposure in a Barrett's adenocarcinoma cell line. Gut 2003, 52:A44.
127. Kaur BS, Triadafilopoulos G: Acid- and bile-induced PGE(2) release and hyperproliferation in Barrett's oesophagus are COX-2 and PKC-epsilon dependent. Am J Physiol Gastrointest Liver Physiol 2002, 283:G327-334.
128. Shirvani VN, Ouatu-Lascar R, Kaur BS, Omary MB, Triadafilopoulos G: Cyclooxygenase 2 expression in Barrett's oesophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 2000, 118:487-496.
129. Kaur B, Omary M, Triadafilopoulos G: Bile salt-induced cell proliferation in an ex vivo model of Barrett's oesophagus is associated with specific PKC isoform modulation. Am J Gastrointest Liver Physiol 2000, 278:G1000-1009.
130. Fitzgerald RC, Omary MB, Triadafilopoulos G: Dynamic effects of acid on Barrett's oesophagus: an ex vivo differentiation and proliferation model. J Clin Invest 1996, 98:2120-2128.
131. Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, Varro A, Dimaline R: Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003, 124:615-625.
132. Going JJ, Keith WN, Neilson L, Stoeber K, Stuart RC, Williams GH: Aberrant expression of minichromosome maintenance proteins 2 and 5, and Ki-67 in dysplastic squamous oesophageal epithelium and Barrett's mucosa. Gut 2002, 50:373-377.
133. Arber N, Lightdale C, Rotterdam H, Han KH, Sgambato A, Yap E, Ahsan H, Finegold J, Stevens PD, Green PH, Hibshoosh H, Neugut AI, Holt PR, Weinstein IB: Increased expression of the cyclin D1 gene in Barrett's oesophagus. Cancer Epidemiol Biomarkers Prev 1996, 5:457-459.
134. Morgan RJ, Newcomb PV, Hardwick RH, Alderson D: Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma. Eur J Surg Oncol 1999, 25:364-367.
135. Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP: Prospective study of cyclin D1 overexpression in Barrett's oesophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 2000, 92:1316-1321.
136. Coppola D, Schreiber RH, Mora L, Dalton W, Karl RC: Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 1999, 6:298-304.
137. Boynton RF, Huang Y, Blount PL, Reid BJ, Raskind WH, Haggitt RC, Newkirk C, Resau JH, Yin J, McDaniel T: Frequent loss of heterozygosity at the retinoblastoma locus in human oesophageal cancers. Cancer Res 1991, 51:5766-5769.
138. Sarbia M, Tekin U, Zeriouh M, Donner A, Gabbert HE: Expression of the RB protein, allelic imbalance of the RB gene and amplification of the CDK4 gene in metaplasias, dysplasias and carcinomas in Barrett's oesophagus. Anticancer Res 2001, 21:387-392.
139. Sarbia M, Bektas N, Muller W, Heep H, Borchard F, Gabbert HE: Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett oesophagus. Cancer 1999, 86:2597-2601.
140. Krishnadath KK, Tilanus HW, van Blankenstein M, Bosman FT, Mulder AH: Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. J Pathol 1995, 175:175-180.
141. Younes M, Lebovitz RM, Lechago LV, Lechago J: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993, 105:1637-1642.
142. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE: Base transitions at CpG dinucleotides in the p53 gene are common in oesophageal adenocarcinoma. Cancer Res 1995, 55:3406-3411.
143. Hamelin R, Flejou JF, Muzeau F, Potet F, Laurent-Puig P, Fekete F, Thomas G: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's oesophagus. Gastroenterology 1994, 107:1012-1018.
144. Casson AG, Manolopoulos B, Troster M, Kerkvliet N, O'Malley F, Inculet R, Finley R, Roth JA: Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive oesophageal cancer. Am J Surg 1994, 167:52-57.
145. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ: p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994, 106:1589-1595.
146. Schneider PM, Casson AG, Levin B, Garewal HS, Hoelscher AH, Becker K, Dittler HJ, Cleary KR, Troster M, Siewert JR, Roth JA: Mutations of p53 in Barrett's oesophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 1996, 111:323-331. discussion 331-333
147. Symmans PJ, Linehan JM, Brito MJ, Filipe MI: p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. J Pathol 1994, 173:221-226.
148. Blount PL, Ramel S, Raskind WH, Haggitt RC, Sanchez CA, Dean PJ, Rabinovitch PS, Reid BJ: 17p allelic deletions and p53 protein overexpression in Barrett's adenocarcinoma. Cancer Res 1991, 51:5482-5486.
149. Klump B, Hsieh CJ, Holzmann K, Borchard F, Gaco V, Greschniok A, Eckardt VF, Bettendorf U, Gregor M, Porschen R: Diagnostic significance of nuclear p53 expression in the surveillance of Barrett's oesophagus - a longitudinal study. Z Gastroenterol 1999, 37:1005-1011.
150. Wong DJ, Barrett MT, Stoger R, Emond MJ, Reid BJ: p16INK4a promoter is hypermethylated at a high frequency in oesophageal adenocarcinomas. Cancer Res 1997, 57:2619-2622.
151. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J: p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's oesophagus. Gastroenterology 2002, 122:1113-1121.
152. Klump B, Hsieh CJ, Holzmann K, Gregor M, Porschen R: Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's oesophagus. Gastroenterology 1998, 115:1381-1386.
153. Wong DJ, Paulson TG, Prevo LJ, Galipeau PC, Longton G, Blount PL, Reid BJ: p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001, 61:8284-8289.
154. Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menendez MJ, Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, Coto E: Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 1997, 50:212-217.
155. Singh SP, Lipman J, Goldman H, Ellis Jr FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M: Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res 1998, 58:1730-1735.
156. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS: Flow-cytometric and histological progression to malignancy in Barrett's oesophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992, 102:1212-1219.
157. Geddert H, Heep HJ, Gabbert HE, Sarbia M: Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett oesophagus. Cancer 2002, 94:212-218.
158. Woodward TA, Klingler PD, Genko PV, Wolfe JT: Barrett's oesophagus, apoptosis and cell cycle regulation: correlation of p53 with Bax, Bcl-2 and p21 protein expression. Anticancer Res 2000, 20:2427-2432.
159. Chatelain D, Flejou JF: High-grade dysplasia and superficial adenocarcinoma in Barrett's oesophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch 2003, 442:18-24.
160. Rioux-Leclercq N, Turlin B, Sutherland F, Heresbach N, Launois B, Campion JP, Ramee MP: Analysis of Ki-67, p53 and Bcl-2 expression in the dysplasia-carcinoma sequence of Barrett's oesophagus. Oncol Rep 1999, 6:877-882.
161. Katada N, Hinder RA, Smyrk TC, Hirabayashi N, Perdikis G, Lund RJ, Woodward T, Klingler PJ: Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett oesophagus. Arch Surg 1997, 132:728-733.
162. Goldblum JR, Rice TW: bcl-2 protein expression in the Barrett's metaplasia-dysplasia-carcinoma sequence. Mod Pathol 1995, 8:866-869.
163. Hanas JS, Lerner MR, Lightfoot SA, Raczkowski C, Kastens DJ, Brackett DJ, Postier RG: Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumour suppressor in dysplastic progression and adenocarcinoma in Barrett oesophagus. Cancer 1999, 86:756-763.
164. Fujii T, Nakagawa S, Hanzawa M, Sueyoshi S, Fujita H, Shirouzu K, Yamana H: Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's oesophagus. Oncol Rep 2003, 10:427-431.
165. Schweigerer L: Fibroblast growth factor and angiogenesis. Z Kardiol 1989, 78(Suppl 6):12-15.
166. Soslow RA, Ying L, Altorki NK: Expression of acidic fibroblast growth factor in Barrett's oesophagus and associated oesophageal adenocarcinoma. J Thorac Cardiovasc Surg 1997, 114:838-843.
167. Soslow RA, Nabeya Y, Ying L, Blundell M, Altorki NK: Acidic fibroblast growth factor is progressively increased in the development of oesophageal glandular dysplasia and adenocarcinoma. Histopathology 1999, 35:31-37.
168. Soslow RA, Petersen CG, Remotti H, Altorki N: Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's oesophagus to oesophageal adenocarcinoma. Dis Esophagus 2001, 14:23-27.
169. Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF: Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2001, 192:14-18.
170. Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002, 20:2971-2979.
171. Crossin KL: Cell adhesion molecules in embryogenesis and disease. Ann N Y Acad Sci 1991, 615:172-186.
172. Bongiorno PF, al-Kasspooles M, Lee SW, Rachwal WJ, Moore JH, Whyte RI, Orringer MB, Beer DG: E-cadherin expression in primary and metastatic thoracic neoplasms and in Barrett's oesophagus. Br J Cancer 1995, 71:166-172.
173. Krishnadath KK, Tilanus HW, van Blankenstein M, Hop WC, Kremers ED, Dinjens WN, Bosman FT: Reduced expression of the cadherin-catenin complex in oesophageal adenocarcinoma correlates with poor prognosis. J Pathol 1997, 182:331-338.
174. Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J: Altered cadherin and catenin complexes in the Barrett's oesophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol 1998, 152:135-144.
175. Swami S, Kumble S, Triadafilopoulos G: E-cadherin expression in gastroesophageal reflux disease, Barrett's oesophagus, and oesophageal adenocarcinoma: an immunohistochemical and immunoblot study. Am J Gastroenterol 1995, 90:1808-1813.
176. Washington K, Chiappori A, Hamilton K, Shyr Y, Blanke C, Johnson D, Sawyers J, Beauchamp D: Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's oesophagus and oesophageal adenocarcinomas. Mod Pathol 1998, 11:805-813.
177. Seery JP, Syrigos KN, Karayiannakis AJ, Valizadeh A, Pignatelli M: Abnormal expression of the E-cadherin-catenin complex in dysplastic Barrett's oesophagus. Acta Oncol 1999, 38:945-948.
178. Bian YS, Osterheld MC, Bosman FT, Fontolliet C, Benhattar J: Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett oesophagus. Am J Clin Pathol 2000, 114:583-590.
179. Zhuang Z, Vortmeyer AO, Mark EJ, Odze R, Emmert-Buck MR, Merino MJ, Moon H, Liotta LA, Duray PH: Barrett's oesophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 1996, 56:1961-1964.
180. Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK: LOH at the sites of the DCC, APC, and TP53 tumour suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the oesophagus. Hum Pathol 1999, 30:1508-1514.
181. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidransky D, Huss HT, Demeester TR, Eads C, Laird PW, Ilson DH, Kelsen DP, Harpole D, Moore MB, Danenberg KD, Danenberg PV, Meltzer SJ: Hypermethylated APC DNA in plasma and prognosis of patients with oesophageal adenocarcinoma. J Natl Cancer Inst 2000, 92:1805-1811.
182. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ: Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999, 22:106-109.
183. Marchetti M, Caliot E, Pringault E: Chronic acid exposure leads to activation of the cd×2 intestinal homeobox gene in a long-term culture of mouse oesophageal keratinocytes. J Cell Sci 2003, 116:1429-1436.
184. Howden CW, Horing CA: Do proton pump inhibitors induce regression of Barrett's oesophagus? A systematic review. Gastroenterology 1997, 112:A152.
185. Katzka DA, Castell DO: Successful elimination of reflux symptoms does not ensure adequate control of acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1994, 89:989-991.
186. Sampliner RE: Effect of up to 3 years of high-dose Lanzoprazole. Am J Gastroenterol 1994, 89:1844-1848.
187. Ouatu-Lascar R, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalisation of intraoesophageal acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1998, 93:711-716.
188. Blot WJ, Devesa SS, Fraumeni JF: Continuing climb in rates of oesophageal carcinoma: an update. JAMA 1993, 270:1320.
189. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR: Increasing incidence of adenocarcinoma of the oesophagus and oesophagogastric junction. Gastroenterology 1993, 104:510-513.
190. Champion G, Richter JE, Vaezi MF, Singh S, Alexander R: Dudodenogastroesophageal reflux: relationship of pH and importance in Barrett's oesophagus. Gastroenterology 1994, 107:747-754.
191. Blustein PK, Beck PL, Meddings JB, Van Rosendaal GM, Bailey RJ, Lalor E, Thomson AB, Verhoef MJ, Sutherland LR: The utility of endoscopy in the management of patients with gastro-oesophageal reflux symptoms. Am J Gastroenterol 1998, 93:2508-2512.
192. Barham CP, Jones RL, Biddlestone LR, Hardwick RH, Shepherd NA, Barr H: Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut 1997, 41:281-284.
193. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N: Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus using photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996, 348:584-585.
194. Bryne JP, Armstrong GR, Attwood SEA: Restoration of the normal squamous lining in Barrett's oesophagus by Argon Bean Coagulation. Am J Gastroenterol 1998, 93:1810-1815.
195. Gossner L, Stolte M, Sroka R, May A, Hahn EG, Ell C: Photodynamic therapy of high-grade dysplasia and early stage carcinomas by means of 5-aminolaevulinic acid. Z Gastroenterol 1998, 36:19-26.
196. Overholt BF, Banjepour M, Haydek JM: Photodynamic therapy for Barrett's oesophagus: follow up in 100 patients. Gastrointestinal Endosc 1999, 49:1-7.
197. van den Boogert J, van Hillegersberg R, Siersema PD, de Bruin RW, Tilanus HW: Endoscopic ablation therapy for Barrett's oesophagus: a review. Am J Gastroenterol 1999, 94:1153-1160.
198. Attwood SEA, Barlow AP, Norris TL, Watson A: Barrett's oesophagus; effect of anti-reflux surgery on symptoms control and development of complications. Br J Surg 1992, 79:1050-1053.
199. Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J, Liron R, Aguilar J: Conservative treatment versus anti-reflux surgery in Barrett's oesophagus: long-term results of a prospective randomised study. Br J Surg 1996, 83:274-278.
200. Skinner DB, Walther BC, Riddell RH, Schmidt H, Iascone C, DeMeester TR: Barrett's oesophagus. Comparison of benign and malignant cases. Ann Surg 1983, 198:554-565.
201. Brand DL, Ylvisader JT, Gelfand M, Pope II CE: Regression of columnar-lined oesophagus (Barrett's) epithelium after anti-reflux surgery. N Engl J Med 1980, 302:844-848.
202. Williamson WA, Ellis Jr FH, Gibb SP, Shahian DM, Aretz HT: Effect of anti-reflux operations on Barrett's mucosa. Ann Thorac Surg 1990, 49:537-541. Discussion 541-542
203. Sagar PM, Ackroyd R, Hosie KB, Patterson JE, Stoddard CJ, Kingsnorth AN: Regression and progression of Barrett's oesophagus after anti-reflux surgery. Br J Surg 1995, 82:806-810.
204. McDonald ML, Trastek VF, Allen MS, Deschamps C, Pairolero PC, Pairolero PC: Barrett's oesophagus; does an anti-reflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996, 111:1135-1138. discussion 1139-1140
205. Wright TA, Kingsnorth AN: Barrett's oesophagus and markers of malignant potential. Eur J Gastroenterol Hepatol 1994, 6:656-662.
206. Lund O, Kimose HH, Aagaard MT, Hasenkam JM, Erlandsen M: Risk stratification and long-term results for carcinoma of the oesophagus. J Thorac Cardiovasc Surg 1990, 99:200-209.
207. Bachmann MO, Alderson D, Edwards D, Wotton S, Bedford C, Petrs TJ, Harvey IM: Cohort study in South and West England of the influence of specialization on the management and outcome of patients with oesophageal and gastric cancers. Br J Surg 2002, 89:914-922.
208. Streitz Jr JM, Ellis Jr FH, Gibb SP, Balogh K, Watkins Jr E: Adenocarinoma in Barrett's oesophagus: a clinicopathologic study of 65. cases.Ann Surg 1991, 213:122-125.
209. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C: Barrett's metaplasia. Lancet 2000, 356:2079-2085.
210. Fitzgerald R, Triadafilopoulos G: Recent developments in the molecular characterization of Barrett's oesophagus. Dig Dis 1998, 16:63-80.
211. Souza RF, Morales CP, Spechler SJ: A conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment Pharmacol Ther 2001, 15:1087-1100.
212. Peters J, Clark G, Ireland A, Chandrasoma P, Smyrk T, DeMeester T: Outcome of adenocarcinoma arising in endoscopically surveyed and nonsurveyed patients. J Thorac Cardiovasc Surg 1994, 108:813-821.
213. Streitz Jr JM, Andrews Jr CW, Ellis Jr FH: Endoscopic surveillance of Barrett's oesophagus. Does it help? J Thorac Cardiovasc Surg 1993, 105:383-387. discussion 387-388
214. van Sandick JW, van Lanschot JJ, Kuiken BW, Tytgat GN, Offerhaus GJ, Obertop H: Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998, 43:216-222.
215. Vanderveen A, Dees J, Blankenstein J: Adenocarcinoma in Barrett's oesophagus: An overrated risk. Gut 1989, 30:14-18.
216. Sonnenberg A, Soni A, Sampliner RE: Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma. Aliment Pharmacol Ther 2002, 16:41-50.
217. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS: Is there publication bias in the reporting of cancer risk in Barrett's oesophagus. Gastroenterology 2000, 119:333-338.
218. Dar MS, Goldblum JR, Rice TW, Falk GW: Can extent of high grade dysplasia in Barrett's oesophagus predict the presence of adenocarcinoma at oesophagectomy? Gut 2003, 52:486-489.
219. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS: Predictors of progression to cancer in Barrett's oesophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000, 95:1669-1676.
220. Rice TW, Falk GW, Achkar E, Petras RE: Surgical management of high-grade dysplasia in Barrett's oesophagus. Am J Gastroenterol 1993, 88:1832-1836.
221. Provenzale D, Schmitt C, Wong J: Barrett's oesophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999, 94:2043-2053.
222. Provenzale D, Kemp J, Arora S, Wong J: A guide for surveillance of patients with Barrett's oesophagus. Am J Gastroenterol 1994, 89:670-680.
223. Reid BJ, Weinstein WM, Lewin KJ, Haggitt RC, VanDeventer G, DenBesten L, Rubin CE: Endoscopic biopsies diagnose high grade dysplasia or early operable adenocarcinoma without grossly recognizable neoplastic lesions. Gastroenterology 1988, 94:81-90.
224. Fitzgerald RC, Saeed IT, Khoo D, Farthing MJ, Burnham WR: Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's oesophagus. Dig Dis Sci 2001, 46:1892-1898.
225. Sampliner RE: Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's oesophagus. Am J Gastroenterol 2002, 97:1888-1895.
226. Wang T, Triadafilopoulos G: S, m, l, xl. Gut 2003, 52:5-7.
227. Pacifico RJ, Wang KK: Nonsurgical management of Barrett's oesophagus with high-grade dysplasia. Surg Oncol Clin N Am 2002, 11:321-336.
228. Fitzgerald RC: Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer. Gut 2003, 52:16-17.
229. Barr H: Ablative mucosectomy is the procedure of choice to prevent Barrett's cancer. Gut 2003, 52:14-15.
230. Fitzgerald RC, Lascar R, Triadafilopoulos G: Review article: Barrett's oesophagus, dysplasia and pharmacologic acid suppression. Aliment Pharmacol Ther 2001, 15:269-276.
231. Dannenberg AJ, Altorki NK, Boyle JO, Lin DT, Subbaramaiah K: Inhibition of cyclooxygenase-2: an approach to preventing cancer of the upper aerodigestive tract. Ann N Y Acad Sci 2001, 952:109-115.